{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:55:10Z","timestamp":1789602910041,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jtct.2023.06.011","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T23:33:04Z","timestamp":1687649584000},"page":"577.e1-577.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-versus-Host Disease"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0024-0699","authenticated-orcid":false,"given":"Rebecca","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Gaskill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Pidala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Lazaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Khimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7750-781X","authenticated-orcid":false,"given":"Rawan","family":"Faramand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.06.011_bib0001","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.06.011_bib0002","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.06.011_bib0003","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","article-title":"Classification systems for chronic graft-versus-host disease","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.06.011_bib0004","series-title":"Rezurock (belumosudil) [package insert]","year":"2021"},{"key":"10.1016\/j.jtct.2023.06.011_bib0005","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.bbmt.2010.06.015","article-title":"Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD","volume":"16","author":"Wolff","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.06.011_bib0006","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2014-03-563544","article-title":"Failure-free survival after initial systemic treatment of chronic graft-versus-host disease","volume":"124","author":"Inamoto","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.06.011_bib0007","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2012-11-465583","article-title":"Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease","volume":"121","author":"Inamoto","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.06.011_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2010.05.011","article-title":"Consensus Conference on Clinical Practice in Chronic GVHD: second-line treatment of chronic graft-versus-host disease","volume":"17","author":"Wolff","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.06.011_bib0009","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1182\/blood.2021014448","article-title":"Three US Food and Drug Administration-approved therapies for chronic GVHD","volume":"139","author":"Zeiser","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.06.011_bib0010","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.06.011_bib0011","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2019-125986","article-title":"KD025 for patients with chronic graft-versus-host disease (cGVHD) - long-term follow-up of a phase 2a study (KD025-208)","volume":"134","author":"Jagasia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.06.011_bib0012","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.bbmt.2017.12.615","article-title":"Initial results of KD025-208: a phase 2a open-label clinical trial of KD025 for steroid-dependent chronic graft-versus-host disease (cGVHD)","volume":"24","author":"Lazaryan","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.06.011_bib0013","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2021-153371","article-title":"Belumosudil for patients with chronic graft-versus-host disease: combined analysis of failure-free survival (FFS) in the KD025-208 and pivotal Rockstar trials","volume":"138","author":"Lazaryan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.06.011_bib0014","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.bbmt.2018.12.100","article-title":"KD025-208: A phase 2a study of KD025 for patients with chronic graft versus host disease (cGVHD)\u2014pharmacodynamics (PD) and updated results","volume":"25","author":"Jagasia","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.06.011_bib0015","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s40265-021-01593-z","article-title":"Belumosudil: first approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jtct.2023.06.011_bib0016","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Rezurock: multi-discipline review. July 16, 2021. Application number: 214783Orig1s000. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/214783Orig1s000MultidisciplineR.pdf. Accessed July 12, 2022."},{"key":"10.1016\/j.jtct.2023.06.011_bib0017","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/cpdd.1082","article-title":"A phase 1 pharmacokinetic drug interaction study of belumosudil coadministered with CYP3A4 inhibitors and inducers and proton pump inhibitors","volume":"11","author":"Schueller","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jtct.2023.06.011_bib0018","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/pgs-2018-0003","article-title":"CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration","volume":"19","author":"Pasternak","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jtct.2023.06.011_bib0019","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/j.1600-6143.2004.00539.x","article-title":"CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs","volume":"4","author":"Lemahieu","year":"2004","journal-title":"sirolimus. Am J Transplant."},{"key":"10.1016\/j.jtct.2023.06.011_bib0020","doi-asserted-by":"crossref","unstructured":"Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389-401.e1. doi: 10.1016\/j.bbmt.2014.12.001","DOI":"10.1016\/j.bbmt.2014.12.001"},{"key":"10.1016\/j.jtct.2023.06.011_bib0021","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/cpdd.388","article-title":"Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects","volume":"7","author":"Kropeit","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jtct.2023.06.011_bib0022","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/j.1600-6143.2009.02768.x","article-title":"A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients","volume":"9","author":"Pescovitz","year":"2009","journal-title":"Am J Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723013593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723013593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:10:33Z","timestamp":1763003433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723013593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2666636723013593"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.06.011","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-versus-Host Disease","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}